NCT00003694View on ClinicalTrials.gov

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

August 31, 2003

Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia
Interventions
DRUG

omacetaxine mepesuccinate

Given IV

DRUG

cytarabine

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02115

Dana-Farber Harvard Cancer Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003694 - Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | Biotech Hunter | Biotech Hunter